LX31 Stock Chart & Stats
€1.01
€0.00(0.00%)
At close: 4:00 PM EDT
€1.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.88 - €1.45
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€889.74M
Enterprise Value€919.00
Total Cash (Recent Filing)€190.61M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding444,196,380
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.37Price Target Upside332.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€32.82M
Bulls Say, Bears Say
Bulls Say
Strengthened Liquidity & Balance SheetMaterially higher cash and a new credit facility extend runway and give management flexibility to fund late-stage trials, precommercial investments, and milestone needs without immediate dilution. This improves financial optionality and lowers near-term insolvency risk during regulatory execution.
Late-stage Pipeline MomentumOver-enrollment in the pivotal SONATA-HCM study increases statistical power and reduces event risk for the primary endpoint, improving the likelihood of a definitive top-line readout. Coupled with planned Zynquista resubmission and LX9851 milestones, this raises the probability of near-term regulatory/partner value realization.
High Gross MarginsExceptionally high gross margins suggest future product or royalty revenues would convert to incremental profit at a high rate. Once fixed R&D and SG&A are covered, this margin profile supports durable operating leverage and attractive economics upon successful commercialization or steady partnership royalties.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$80M TTM) indicates the company is consuming cash to fund development and operations. Continued burn increases dependence on external financing, heightens dilution risk or covenant pressure, and could constrain investment if additional capital is delayed or terms worsen.
Revenue Volatility And Limited Commercial SalesRevenue is highly lumpy and driven by licensing/milestone timing rather than recurring product sales. The steep year-over-year decline highlights reliance on partner-triggered payments, leaving operating costs exposed to financing cycles and making sustainable margin improvement dependent on achieving stable commercial revenue streams.
Regulatory And Funding ConditionalityDependence on investigator-initiated data for NDA exposure and conditional availability of additional Hercules tranches increases execution risk. Third-party timing, data formatting challenges, or unmet milestone conditions can delay regulatory actions, postpone milestone receipts, and strain liquidity ahead of commercialization.
Lexicon Pharmaceuticals News
LX31 FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was €0.88 and its highest was €1.45 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is €889.74M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 94 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -€0.061 earnings per share for the quarter, missing the consensus estimate of -€0.043 by -€0.017.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,196,380 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -€0.061 in its last earnings report, missing expectations of -€0.043. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:LX31
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.37 (332.51% Upside)
€4.37 (332.51% Upside)
Blogger Sentiment
Bullish
DE:LX31 Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.85%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LX31 Company Deck
LX31 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful clinical and strategic progress — notably the over-enrollment of SONATA-HCM, approaching NDA resubmission for Zynquista supported by favorable STENO1 exposure and DKA data, international regulatory activity, and milestone-driven partnership progress (LX9851) — and the company strengthened liquidity with cash rising to $190.6M and a new Hercules loan facility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by lack of prior-period licensing revenue), a return to a net loss of $31.8M, increased R&D spending, and some timing uncertainty due to reliance on an investigator-led study for NDA formatting and submission. Overall, the call presented strong operational and pipeline momentum alongside expected near-term financial volatility as the company invests in late-stage programs.View all DE:LX31 earnings summariesLX31 Stock 12 Month Forecast
Average Price Target
€4.37
▲(332.51% Upside)